Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPLIFY: Acalabrutinib and Venetoclax with or without Obinutuzumab in previously untreated Chronic Lymphocytic Leukemia
NCT03836261Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Feb 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by Acerta Pharma. Started Feb 2019; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03836261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836261.